概括
以每分钟3000转的速度振荡3分钟,通过脱聚合血小板,有效地减轻了伪血小板缺血症 (PTCP). 这种方法显著改善了血小板数量,并为PTCP管理提供了有前途的临床解决方案.
科学领域:
- 血液学 血液学 血液学
- 生物物理学的生物物理.
背景情况:
- 伪血栓细胞衰减 (PTCP) 是一种预分析条件,可能导致误诊.
- 在体外血小板 (PLT) 凝聚需要有效的脱聚合策略.
研究的目的:
- 评估振荡诱导脱聚合物的有效性,以控制PTCP.
- 为了确定血小板脱聚合的最佳振荡条件.
主要方法:
- 161名PTCP患者根据振荡参数 (1500rpm/1分钟,1500rpm/3分钟,3000rpm/1分钟,3000rpm/3分钟) 分为四组.
- 血小板脱聚合率在振荡前和振荡后使用血液学分析仪和特殊染料进行评估.
- 检查了周围血液涂抹以检查血小板的分布.
主要成果:
- 3,000rpm的振荡显著增加了PLT计数,而不是1500rpm (p <0.05).
- 最高的脱聚合率 (93.79%) 实现了3000rpm 3分钟,明显超过了特殊染色方法 (11.80%).
- 淋巴细胞数量增加和是不完全脱聚合的危险因素; bilirubin 水平是保护性的.
结论:
- 在PTCP中,在每分钟3000转的3分钟振荡对于血小板脱聚合非常有效.
- 监测特定的血液参数可以帮助及时应用这种振荡方法,以准确的临床检测.
更多相关视频
09:38A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time
Published on: February 14, 2017
14.3K
06:16Author Spotlight: Advancing Thrombolytic Testing by Integrating Flow Dynamics in In Vitro Models
Published on: April 19, 2024
1.7K
相关概念视频
Venous Thrombosis III: Interprofessional Care
265
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
265
Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.6K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.0K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.0K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.0K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.0K
Clot Retraction and Fibrinolysis
8.3K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
8.3K
Disorders of Hemostasis
2.0K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.0K
